Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

25 questions · 25 findings · 2 reviews

No studies found 2 · 8%GRADE not reported 0 · 0%Very low 13 · 52%Low 4 · 16%Moderate 6 · 24%High 0 · 0%

Antiplatelet agent vs control

Fatal or nonfatal myocardial infarction · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents probably leads to lower fatal or nonfatal myocardial infarction compared with control (moderate certainty).

1 finding from 1 review

Antiplatelet agent vs control

Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).

1 finding from 1 review

Antiplatelet agent vs control

Death (any cause) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).

1 finding from 1 review

Antiplatelet agent vs control

Cardiovascular mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).

1 finding from 1 review

Antiplatelet agent vs control

Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).

1 finding from 1 review

Antiplatelet agent vs control

Minor bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).

1 finding from 1 review

Antiplatelet agent vs control

Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).

1 finding from 1 review

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).

1 finding from 1 review